{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:38:42Z","timestamp":1789115922280,"version":"build-2803163510"},"reference-count":192,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"1","funder":[{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["EP\/W524694\/1"],"award-info":[{"award-number":["EP\/W524694\/1"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["spj.science.org"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:p>T-cell engagers (TCEs) are immunotherapeutic drugs that are gaining interest and momentum in oncology, and since 2022, they have been increasingly approved for clinical use. However, there are still many issues and unknowns relating to their pharmacokinetics, efficacy, and adverse side effects. Mathematical models are in the perfect position to improve understanding of these key issues, expand on, and optimize currently approved TCEs. This paper will review the relevant biology behind TCEs, such as the mechanisms behind the antitumor response, the molecular biology of TCE construction, and their use in clinical settings. Then, the review will move to discuss TCE mathematical modeling, key methods, and conclusions to date.<\/jats:p>","DOI":"10.34133\/csbj.0209","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:57:17Z","timestamp":1785790637000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An Overview on T-Cell Engagers: The Current Position in Both the Biological and Mathematical Context"],"prefix":"10.34133","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9272-7730","authenticated-orcid":true,"given":"Jonathan","family":"Davies","sequence":"first","affiliation":[{"name":"Department of Mathematics, \rSwansea University, Swansea, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9870-8418","authenticated-orcid":false,"given":"Liam V.","family":"Brown","sequence":"additional","affiliation":[{"name":"Early Oncology DMPK, Oncology Targeted Discovery, AstraZeneca","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8991-1190","authenticated-orcid":false,"given":"Mark W.","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Computer Science, \rSwansea University, Swansea, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Penney","sequence":"additional","affiliation":[{"name":"Early Oncology DMPK, Oncology Targeted Discovery, AstraZeneca","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8372-7349","authenticated-orcid":true,"given":"Gibin","family":"Powathil","sequence":"additional","affiliation":[{"name":"Department of Mathematics, \rSwansea University, Swansea, UK."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Sompayrac L. How the immune system works. Seventh edition. Hoboken (NJ) and Chichester: Wiley Blackwell; 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1835-0"},{"issue":"2","key":"e_1_3_3_4_2","first-page":"112","article-title":"Development of dendritic cell system","volume":"1","author":"Li W","year":"2004","unstructured":"Li W, Dakic A. Development of dendritic cell system. Cell Mol Immunol. 2004;1(2):112\u2013118.","journal-title":"Cell Mol Immunol"},{"issue":"10","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMp068087","article-title":"T-cell costimulation\u2014Biology, therapeutic potential, and challenges","volume":"355","author":"Sharpe AH","year":"2006","unstructured":"Sharpe AH, Abbas AK. T-cell costimulation\u2014Biology, therapeutic potential, and challenges. N Engl J Med. 2006;355(10):973\u2013975.","journal-title":"N Engl J Med"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtbi.2013.06.016"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610019104"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20001021"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-251124"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15010132"},{"issue":"8","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.3390\/cancers16081580","article-title":"T-cell engagers\u2014The structure and functional principle and application in hematological malignancies","volume":"16","author":"Cech P","year":"2024","unstructured":"Cech P, Sk\u00f3rka K, Dziki L, Giannopoulos K. T-cell engagers\u2014The structure and functional principle and application in hematological malignancies. Cancer. 2024;16(8):1580.","journal-title":"Cancer"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/314628a0"},{"issue":"5","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1073\/pnas.83.5.1453","article-title":"Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity","volume":"83","author":"Staerz UD","year":"1986","unstructured":"Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA. 1986;83(5):1453\u20131457.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fonc.2020.00446","article-title":"Perspective: Designing T-cell engagers with better therapeutic windows","volume":"10","author":"Vafa O","year":"2020","unstructured":"Vafa O, Trinklein ND. Perspective: Designing T-cell engagers with better therapeutic windows. Front Oncol. 2020;10:446.","journal-title":"Front Oncol"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.02.004"},{"issue":"16","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in escherichia coli","volume":"85","author":"Huston JS","year":"1988","unstructured":"Huston JS, Levinson D, Mudgett-Hunter M, Tai M-S, Novotn\u1ef3 J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, Crea R. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in escherichia coli. Proc Natl Acad Sci USA. 1988;85(16):5879\u20135883.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"e_1_3_3_17_2","doi-asserted-by":"crossref","DOI":"10.4110\/in.2022.22.e4","article-title":"Development of bispecific antibody for cancer immunotherapy: Focus on T cell engaging antibody","volume":"22","author":"Moon D","year":"2022","unstructured":"Moon D, Tae N, Park Y, Lee S-W, Kim DH. Development of bispecific antibody for cancer immunotherapy: Focus on T cell engaging antibody. Immune Network. 2022;22(1): Article e4.","journal-title":"Immune Network"},{"issue":"15","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack M","year":"1995","unstructured":"Mack M, Riethm\u00fcller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA. 1995;92(15):7021\u20137025.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers\u2014Current landscape and future directions","volume":"15","author":"Shanshal M","year":"2023","unstructured":"Shanshal M, Caimi PF, Adjei AA, Ma WW. T-cell engagers in solid cancers\u2014Current landscape and future directions. Cancer. 2023;15(10):2824.","journal-title":"Cancer"},{"key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40164-017-0072-7","article-title":"The development of bispecific antibodies and their applications in tumor immune escape","volume":"6","author":"Zhang X","year":"2017","unstructured":"Zhang X, Yang Y, Fan D, Xiong D. The development of bispecific antibodies and their applications in tumor immune escape. Exp Hematol Oncol. 2017;6:12.","journal-title":"Exp Hematol Oncol"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0227-0"},{"issue":"8","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40265-024-02070-z","article-title":"Tarlatamab: First approval","volume":"84","author":"Dhillon S","year":"2024","unstructured":"Dhillon S. Tarlatamab: First approval. Drugs. 2024;84(8):995\u20131003.","journal-title":"Drugs"},{"issue":"1","key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou S","year":"2021","unstructured":"Zhou S, Liu M, Ren F, Meng X, Jinming Y. The landscape of bispecific T cell engager in cancer treatment. Biomark Res. 2021;9(1):38.","journal-title":"Biomark Res"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0598-2"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3389\/fimmu.2017.00175","article-title":"Antigen loss variants: Catching hold of escaping foes","volume":"8","author":"Vyas M","year":"2017","unstructured":"Vyas M, M\u00fcller R, Pogge E, von Strandmann. Antigen loss variants: Catching hold of escaping foes. Front Immunol. 2017;8:175.","journal-title":"Front Immunol"},{"issue":"11","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003679","article-title":"For whom the T cells troll? Bispecific T-cell engagers in glioblastoma","volume":"9","author":"Singh K","year":"2021","unstructured":"Singh K, Hotchkiss KM, Mohan AA, Reedy JL, Sampson JH, Khasraw M. For whom the T cells troll? Bispecific T-cell engagers in glioblastoma. J Immunother Cancer. 2021;9(11): Article e003679.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","article-title":"Resistance to anti-CD19\/CD3 bite in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking","volume":"129","author":"Braig F","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, Tony H-P, Kurze A-K, Nollau P, Bumm T, B\u00f6ttcher S, Bargou RC, Binder M. Resistance to anti-CD19\/CD3 bite in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129(1):100\u2013104.","journal-title":"Blood"},{"issue":"4","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.2020006287","article-title":"Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with B-ALL","volume":"137","author":"Zhao Y","year":"2021","unstructured":"Zhao Y, Aldoss I, Chunxu Q, Crawford JC, Zhaohui G, Allen EK, Zamora AE, Alexander TB, Wang J, Goto H, et al. Tumor-intrinsic and-extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood. 2021;137(4):471\u2013484.","journal-title":"Blood"},{"key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"1583044","DOI":"10.3389\/fimmu.2025.1583044","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao L","year":"2025","unstructured":"Cao L, Leclercq-Cohen G, Klein C, Sorrentino A, Bacac M. Mechanistic insights into resistance mechanisms to T cell engagers. Front Immunol. 2025;16:1583044.","journal-title":"Front Immunol"},{"issue":"11","key":"e_1_3_3_31_2","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9 E","year":"2024","unstructured":"Letouz\u00e9 E, Moreau P, Munshi N, Samur M, Minvielle S, Touzeau C. Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications. Blood Adv. 2024;8(11):2952\u20132959.","journal-title":"Blood Adv"},{"issue":"10","key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.4049\/jimmunol.177.10.7435","article-title":"Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia","volume":"177","author":"Williams ME","year":"2006","unstructured":"Williams ME, Densmore JJ, Pawluczkowycz AW, Beum PV, Kennedy AD, Lindorfer MA, Hamil SH, Eggleton JC, Taylor RP. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia. J Immunol. 2006;177(10):7435\u20137443.","journal-title":"J Immunol"},{"issue":"12","key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3390\/medicina61122113","article-title":"Mechanistic insights and advances of bispecific T cell engaging antibodies therapy in multiple myeloma","volume":"61","author":"Tang TF","year":"2025","unstructured":"Tang TF, Cheong CS, Looi CY, Wong WF, Gan GG. Mechanistic insights and advances of bispecific T cell engaging antibodies therapy in multiple myeloma. Medicina. 2025;61(12):2113.","journal-title":"Medicina"},{"issue":"6","key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.4049\/jimmunol.1101189","article-title":"Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells","volume":"187","author":"Beum PV","year":"2011","unstructured":"Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, van de Winkel JGJ, Taylor RP. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells. J Immunol. 2011;187(6):3438\u20133447.","journal-title":"J Immunol"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1054-1"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"issue":"6","key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau P","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505.","journal-title":"N Engl J Med"},{"issue":"10396","key":"e_1_3_3_38_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"Donk NWCJ","year":"2023","unstructured":"van de Donk NWCJ, Zweegman S. T-cell-engaging bispecific antibodies in cancer. Lancet. 2023;402(10396):142\u2013158.","journal-title":"Lancet"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-017-4943-5"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050355"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.03.005"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2011.01.034"},{"key":"e_1_3_3_46_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-019-0356-0","article-title":"Response to IL-6 trans-and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: Fusing experimental insights and dynamic modelling","volume":"17","author":"Reeh H","year":"2019","unstructured":"Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E, Schliemann-Bullinger M, Findeisen R, Schaper F, Huber HJ, et al. Response to IL-6 trans-and IL-6 classic signalling is determined by the ratio of the IL-6 receptor \u03b1 to gp130 expression: Fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019;17:46.","journal-title":"Cell Commun Signal"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90055-K"},{"issue":"12","key":"e_1_3_3_48_2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: A critical update","volume":"111","author":"Pepys MB","year":"2003","unstructured":"Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest. 2003;111(12):1805\u20131812.","journal-title":"J Clin Invest"},{"issue":"224","key":"e_1_3_3_49_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila ML","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224): Article 224ra25.","journal-title":"Sci Transl Med"},{"issue":"2","key":"e_1_3_3_50_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed A","year":"2024","unstructured":"Sayed A, Munir M, Ghazi SM, Ferdousi M, Krishan S, Shaaban A, Habib A, Kola-Kehinde O, Ruz P, Khan S, et al. Cardiovascular toxicities associated with bispecific T-cell engager therapy. J Immunother Cancer. 2024;12(2): Article e008518.","journal-title":"J Immunother Cancer"},{"issue":"24","key":"e_1_3_3_51_2","doi-asserted-by":"crossref","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir M","year":"2024","unstructured":"Munir M, Sayed A, Addison D, Epperla N. Cardiovascular toxicities associated with novel cellular immune therapies. Blood Adv. 2024;8(24):6282\u20136296.","journal-title":"Blood Adv"},{"key":"e_1_3_3_52_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112986","article-title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","volume":"191","author":"Hassel JC","year":"2023","unstructured":"Hassel JC, Berking C, Forschner A, Gebhardt C, Heinzerling L, Meier F, Ochsenreither S, Siveke J, Hauschild A, Schadendorf D. Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp. Eur J Cancer. 2023;191: Article 112986.","journal-title":"Eur J Cancer"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1131"},{"issue":"11","key":"e_1_3_3_54_2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1159\/000547111","article-title":"Bispecific T-cell engagers-induced interstitial lung disease: Two case reports confirmed by transbronchial lung cryobiopsy","volume":"104","author":"Morviducci M","year":"2025","unstructured":"Morviducci M, Maraz F, Ravaglia C, Petrarulo S, Dubini A, Costantini M, Diano D, Blasi F, Palange P, Piciucchi S, et al. Bispecific T-cell engagers-induced interstitial lung disease: Two case reports confirmed by transbronchial lung cryobiopsy. Respiration. 2025;104(11):880\u2013886.","journal-title":"Respiration"},{"key":"e_1_3_3_55_2","article-title":"Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer","volume":"60","author":"Takahara M","year":"2026","unstructured":"Takahara M, Mouri A, Yamaguchi O, Uno T, Hashimoto K, Imai H, Kagamu H, Kaira K. Synchronous occurrence of interstitial lung disease and ICANS after tarlatamab initiation in recurrent small-cell lung cancer. Respir Med Case Rep. 2026;60: Article 102395.","journal-title":"Respir Med Case Rep"},{"issue":"1","key":"e_1_3_3_56_2","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/s41598-020-58600-8","article-title":"Integrative network modeling reveals mechanisms underlying T cell exhaustion","volume":"10","author":"Bolouri H","year":"2020","unstructured":"Bolouri H, Young M, Beilke J, Johnson R, Fox B, Huang L, Santini CC, Hill CM, Vries AVV, Shannon PT, et al. Integrative network modeling reveals mechanisms underlying T cell exhaustion. Sci Rep. 2020;10(1):1915.","journal-title":"Sci Rep"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-090222-110914"},{"issue":"4","key":"e_1_3_3_58_2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/ijc.25397","article-title":"PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients","volume":"128","author":"Shi F","year":"2011","unstructured":"Shi F, Shi M, Zeng Z, Qi R-Z, Liu Z-W, Zhang J-Y, Yang Y-P, Tien P, Wang F-S. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128(4):887\u2013896.","journal-title":"Int J Cancer"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1679"},{"issue":"33","key":"e_1_3_3_60_2","doi-asserted-by":"crossref","first-page":"14733","DOI":"10.1073\/pnas.1009731107","article-title":"Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection","volume":"107","author":"Jin H-T","year":"2010","unstructured":"Jin H-T, Anderson AC, Tan WG, West EE, Ha S-J, Araki K, Freeman GJ, Kuchroo VK, Ahmed R. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA. 2010;107(33):14733\u201314738.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"38","key":"e_1_3_3_61_2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis N","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38): Article eabd2712.","journal-title":"Sci Adv"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2326"},{"issue":"4","key":"e_1_3_3_63_2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/JVI.01579-09","article-title":"Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: Implications for CD8 T-cell exhaustion","volume":"84","author":"Blackburn SD","year":"2010","unstructured":"Blackburn SD, Crawford A, Shin H, Polley A, Freeman GJ, John E, Wherry. Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: Implications for CD8 T-cell exhaustion. J Virol. 2010;84(4):2078\u20132089.","journal-title":"J Virol"},{"key":"e_1_3_3_64_2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11864-018-0562-9","article-title":"Treatment of complications from immune checkpoint inhibition in patients with lung cancer","volume":"19","author":"Wills B","year":"2018","unstructured":"Wills B, Brahmer JR, Naidoo J. Treatment of complications from immune checkpoint inhibition in patients with lung cancer. Curr Treat Options in Oncol. 2018;19:46.","journal-title":"Curr Treat Options in Oncol"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80069-7"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01264.x"},{"issue":"3","key":"e_1_3_3_67_2","first-page":"186","article-title":"Activation-induced cell death in T cells and autoimmunity","volume":"1","author":"Zhang J","year":"2004","unstructured":"Zhang J, Xuemei X, Liu Y. Activation-induced cell death in T cells and autoimmunity. Cell Mol Immunol. 2004;1(3):186\u2013192.","journal-title":"Cell Mol Immunol"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.4.2183"},{"issue":"16","key":"e_1_3_3_69_2","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1021\/ja311795d","article-title":"A comprehensive mathematical model for three-body binding equilibria","volume":"135","author":"Douglass Jr EF","year":"2013","unstructured":"Douglass Jr EF, Miller CJ, Sparer G, Shapiro H, Spiegel DA. A comprehensive mathematical model for three-body binding equilibria. J Am Chem Soc. 2013;135(16):6092\u20136099.","journal-title":"J Am Chem Soc"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0594"},{"issue":"2","key":"e_1_3_3_71_2","first-page":"2089","article-title":"Decoupling individual host response and immune cell engager cytotoxic potency","volume":"19","author":"Aimard A","year":"2024","unstructured":"Aimard A, Biarnes-P\u00e9licot M, Kerfelec B, Puech P, Robert P, Piazza F, Chames P, Limozin L. Decoupling individual host response and immune cell engager cytotoxic potency. ACS Nano. 2024;19(2):2089\u20132098.","journal-title":"ACS Nano"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2023.12.012"},{"issue":"10","key":"e_1_3_3_73_2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","article-title":"Glofitamab: First approval","volume":"83","author":"Shirley M","year":"2023","unstructured":"Shirley M. Glofitamab: First approval. Drugs. 2023;83(10):935\u2013941.","journal-title":"Drugs"},{"issue":"15","key":"e_1_3_3_74_2","first-page":"4157","article-title":"Effect of bivalent interaction upon apparent antibody affinity: Experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays","volume":"52","author":"Kaufman EN","year":"1992","unstructured":"Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: Experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res. 1992;52(15):4157\u20134167.","journal-title":"Cancer Res"},{"issue":"21","key":"e_1_3_3_75_2","doi-asserted-by":"crossref","first-page":"11337","DOI":"10.1074\/jbc.M116.714287","article-title":"A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets","volume":"291","author":"Rhoden JJ","year":"2016","unstructured":"Rhoden JJ, Dyas GL, Wroblewski VJ. A modeling and experimental investigation of the effects of antigen density, binding affinity, and antigen expression ratio on bispecific antibody binding to cell surface targets. J Biol Chem. 2016;291(21):11337\u201311347.","journal-title":"J Biol Chem"},{"key":"e_1_3_3_76_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112609","article-title":"Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors","volume":"138","author":"Liu J","year":"2024","unstructured":"Liu J, Zhu J. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors. Int Immunopharmacol. 2024;138: Article 112609.","journal-title":"Int Immunopharmacol"},{"key":"e_1_3_3_77_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2675"},{"issue":"6","key":"e_1_3_3_78_2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1158\/1078-0432.CCR-20-2448","article-title":"T-cell\u2013engaging therapy for solid tumors","volume":"27","author":"Miguel M","year":"2021","unstructured":"de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E. T-cell\u2013engaging therapy for solid tumors. Clin Cancer Res. 2021;27(6):1595\u20131603.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000869"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-070620-104325"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407"},{"issue":"1","key":"e_1_3_3_82_2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12943-024-02175-9","article-title":"Targeting mitochondria: Restoring the antitumor efficacy of exhausted T cells","volume":"23","author":"Yang M-Q","year":"2024","unstructured":"Yang M-Q, Zhang S-L, Sun L, Huang L-T, Jing Y, Zhang J-H, Tian Y, Han C-B, Ma J-T. Targeting mitochondria: Restoring the antitumor efficacy of exhausted T cells. Mol Cancer. 2024;23(1):260.","journal-title":"Mol Cancer"},{"key":"e_1_3_3_83_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36967","article-title":"Topography of cancer-associated immune cells in human solid tumors","volume":"7","author":"Kather JN","year":"2018","unstructured":"Kather JN, Suarez-Carmona M, Charoentong P, Weis C-A, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, et al. Topography of cancer-associated immune cells in human solid tumors. eLife. 2018;7: Article e36967.","journal-title":"eLife"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.12.011"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501"},{"key":"e_1_3_3_86_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805"},{"key":"e_1_3_3_87_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20908"},{"key":"e_1_3_3_88_2","doi-asserted-by":"crossref","first-page":"1335689","DOI":"10.3389\/fimmu.2024.1335689","article-title":"Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma","volume":"15","author":"Tiantian Y","year":"2024","unstructured":"Tiantian Y, Xu-Monette ZY, Lagoo A, Shuai W, Wang B, Neff J, Carrillo LF, Carlsen ED, Pina-Oviedo S, Young KH. Flow cytometry quantification of tumor-infiltrating lymphocytes to predict the survival of patients with diffuse large B-cell lymphoma. Front Immunol. 2024;15:1335689.","journal-title":"Front Immunol"},{"key":"e_1_3_3_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01089-x"},{"issue":"1","key":"e_1_3_3_90_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1208\/s12248-021-00637-2","article-title":"A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in\u00a0vitro time course experiments and streamlined data analysis: Improved in\u00a0vitro analysis of CD3-bispecifics","volume":"24","author":"Van De Vyver A","year":"2021","unstructured":"Van De Vyver A, Eigenmann M, Ovacik M, Pohl C, Herter S, Weinzierl T, Fauti T, Klein C, Lehr T, Bacac M, et al. A novel approach for quantifying the pharmacological activity of T-cell engagers utilizing in\u00a0vitro time course experiments and streamlined data analysis: Improved in\u00a0vitro analysis of CD3-bispecifics. AAPS J. 2021;24(1):7.","journal-title":"AAPS J"},{"key":"e_1_3_3_91_2","doi-asserted-by":"crossref","first-page":"2181016","DOI":"10.1080\/19420862.2023.2181016","article-title":"Strategies for clinical dose optimization of T cell-engaging therapies in oncology","volume":"15","author":"Ball K","year":"2023","unstructured":"Ball K, Dovedi SJ, Vajjah P, Phipps A. Strategies for clinical dose optimization of T cell-engaging therapies in oncology. MAbs. 2023;15:2181016.","journal-title":"MAbs"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0074-5"},{"issue":"3","key":"e_1_3_3_93_2","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cpt.3361","article-title":"Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology","volume":"116","author":"Elmeliegy M","year":"2024","unstructured":"Elmeliegy M, Chen J, Dontabhaktuni A, Gaudy A, Kapitanov GI, Li J, Mim SR, Sharma S, Sun Q, Ait-Oudhia S. Dosing strategies and quantitative clinical pharmacology for bispecific T-cell engagers development in oncology. Clin Pharmacol Ther. 2024;116(3):637\u2013646.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_3_94_2","unstructured":"Study of the BiTE blinatumomab (MT103) in adult patients with relapsed\/refractory B-precursor acute lymphoblastic leukemia (ALL). ClinicalTrials.gov Identifier NCT01209286."},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114075"},{"key":"e_1_3_3_96_2","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1200\/JCO.2019.37.15_suppl.7518","article-title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-up dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (NHL)","volume":"37","author":"Bartlett NL","year":"2019","unstructured":"Bartlett NL, Sehn LH, Assouline SE, Bosch F, Diefenbach CM, Flinn I, Hong J, Kim WS, Matasar MJ, Nastoupil L, et al. Managing cytokine release syndrome (CRS) and neurotoxicity with step-up dosing of mosunetuzumab in relapsed\/refractory (R\/R) B-cell non-hodgkin lymphoma (NHL). J Clin Oncol. 2019;37:7518.","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_97_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12874-018-0638-z","article-title":"How to design a dose-finding study using the continual reassessment method","volume":"19","author":"Wheeler GM","year":"2019","unstructured":"Wheeler GM, Mander AP, Bedding A, Brock K, Cornelius V, Grieve AP, Jaki T, Love SB, Odondi L\u2019o, Weir CJ, et al. How to design a dose-finding study using the continual reassessment method. BMC Med Res Methodol. 2019;19:18.","journal-title":"BMC Med Res Methodol"},{"key":"e_1_3_3_98_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12874-021-01218-9","article-title":"Phase I dose-escalation oncology trials with sequential multiple schedules","volume":"21","author":"G\u00fcnhan BK","year":"2021","unstructured":"G\u00fcnhan BK, Weber S, Seroutou A, Friede T. Phase I dose-escalation oncology trials with sequential multiple schedules. BMC Med Res Methodol. 2021;21:69.","journal-title":"BMC Med Res Methodol"},{"issue":"36","key":"e_1_3_3_99_2","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","article-title":"Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"34","author":"Stackelberg A","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O\u2019brien MM, Brethon B, Bhojwani D, et al. Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol. 2016;34(36):4381\u20134389.","journal-title":"J Clin Oncol"},{"issue":"21","key":"e_1_3_3_100_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1182\/blood.V124.21.986.986","article-title":"Hydroxyurea is most suitable for cytoreduction of AML prior to CD33\/CD3 bispecific BiTE antibody (AMG 330) therapy: Uncompromised T-cell proliferation ex-vivo and CD33 upregulation on AML cells","volume":"124","author":"Krupka C","year":"2014","unstructured":"Krupka C, Brauneck F, Lichtenegger FS, Kufer P, Kischel R, Zugmaier G, K\u00f6hnke T, Altmann T, Schneider S, Fiegl M, et al. Hydroxyurea is most suitable for cytoreduction of AML prior to CD33\/CD3 bispecific BiTE antibody (AMG 330) therapy: Uncompromised T-cell proliferation ex-vivo and CD33 upregulation on AML cells. Blood. 2014;124(21):986.","journal-title":"Blood"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.10.020"},{"key":"e_1_3_3_103_2","volume-title":"StatPearls [Internet]","author":"Hodgens A","year":"2023","unstructured":"Hodgens A, Sharman T. Corticosteroids. In: StatPearls [Internet]. StatPearls Publishing; 2023."},{"issue":"6","key":"e_1_3_3_104_2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4187\/respcare.06314","article-title":"Clinical pharmacology of corticosteroids","volume":"63","author":"Williams DM","year":"2018","unstructured":"Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655\u2013670.","journal-title":"Respir Care"},{"key":"e_1_3_3_105_2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu D","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma Clin Immunol. 2013;9:30.","journal-title":"Allergy, Asthma Clin Immunol"},{"issue":"177","key":"e_1_3_3_106_2","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens RJ","year":"2013","unstructured":"Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177): Article 177ra38.","journal-title":"Sci Transl Med"},{"issue":"2","key":"e_1_3_3_107_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu S","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, Tong W, Chen D, Chang AH, Gao Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10(2):15.","journal-title":"Blood Cancer J"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_3_3_109_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.042"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0389-y"},{"issue":"2","key":"e_1_3_3_111_2","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70609","article-title":"T-cell exhaustion from a multiomics perspective: Differentiation mechanisms and regulatory networks in the journey from progenitor-exhausted T cells to terminally exhausted T cells","volume":"16","author":"Zhu T","year":"2026","unstructured":"Zhu T, Teng X, Jiao Q, Ren Y, Wang Y, Feng M. T-cell exhaustion from a multiomics perspective: Differentiation mechanisms and regulatory networks in the journey from progenitor-exhausted T cells to terminally exhausted T cells. Clin Transl Med. 2026;16(2): Article e70609.","journal-title":"Clin Transl Med"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6"},{"issue":"6","key":"e_1_3_3_113_2","first-page":"499","article-title":"Revolutionizing tumor immunotherapy: Unleashing the power of progenitor exhausted T cells","volume":"21","author":"Fang Z","year":"2024","unstructured":"Fang Z, Ding X, Huang H, Jiang H, Jiang J, Zheng X. Revolutionizing tumor immunotherapy: Unleashing the power of progenitor exhausted T cells. Cancer Biol Med. 2024;21(6):499\u2013512.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"e_1_3_3_114_2","doi-asserted-by":"crossref","first-page":"6858","DOI":"10.1038\/s41467-023-42634-3","article-title":"Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through hif-1\u03b1-mediated glycolytic reprogramming","volume":"14","author":"Hao W","year":"2023","unstructured":"Hao W, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Kn\u00f6pper K, Mansilla AM, \u00d6ner A, Doucet-Ladev\u00e8ze R, Schmitz W, et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through hif-1\u03b1-mediated glycolytic reprogramming. Nat Commun. 2023;14(1):6858.","journal-title":"Nat Commun"},{"issue":"5","key":"e_1_3_3_115_2","first-page":"460","article-title":"The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity","volume":"22","author":"Zhong T","year":"2025","unstructured":"Zhong T, Sun S, Zhao M, Zhang B, Xiong H. The mechanisms and clinical significance of CD8+ T cell exhaustion in anti-tumor immunity. Cancer Biol Med. 2025;22(5):460\u2013480.","journal-title":"Cancer Biol Med"},{"issue":"1","key":"e_1_3_3_116_2","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltad013","article-title":"Combination therapies for the optimisation of bispecific T-cell engagers in cancer treatment","volume":"3","author":"Zhu WM","year":"2023","unstructured":"Zhu WM, Middleton MR. Combination therapies for the optimisation of bispecific T-cell engagers in cancer treatment. Immunother Adv. 2023;3(1): Article ltad013.","journal-title":"Immunother Adv"},{"key":"e_1_3_3_117_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0213-6"},{"key":"e_1_3_3_118_2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12185-020-03047-w","article-title":"Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis","volume":"113","author":"Kobayashi T","year":"2021","unstructured":"Kobayashi T, Ubukawa K, Fujishima M, Takahashi N. Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis. Int J Hematol. 2021;113:600\u2013605.","journal-title":"Int J Hematol"},{"issue":"2","key":"e_1_3_3_119_2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001141","article-title":"Combination therapy with T cell engager and Pd-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model","volume":"8","author":"Ma H","year":"2020","unstructured":"Ma H, Wang H, Sov\u00e9 RJ, Wang J, Giragossian C, Popel AS. Combination therapy with T cell engager and Pd-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. J Immunother Cancer. 2020;8(2): Article e001141.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"e_1_3_3_120_2","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.18632\/oncotarget.13888","article-title":"Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition","volume":"8","author":"Deppisch N","year":"2016","unstructured":"Deppisch N, Ruf P, Ei\u00dfler N, Lindhofer H, Mocikat R. Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. Oncotarget. 2016;8(3):4520.","journal-title":"Oncotarget"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801472"},{"issue":"3","key":"e_1_3_3_122_2","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.4049\/jimmunol.181.3.1806","article-title":"Ctla4 expression is an indicator and regulator of steady-state CD4+ Foxp3+ T cell homeostasis","volume":"181","author":"Tang AL","year":"2008","unstructured":"Tang AL, Teijaro JR, Njau MN, Chandran SS, Azimzadeh A, Nadler SG, Rothstein DM, Farber DL. Ctla4 expression is an indicator and regulator of steady-state CD4+ Foxp3+ T cell homeostasis. J Immunol. 2008;181(3):1806\u20131813.","journal-title":"J Immunol"},{"issue":"12","key":"e_1_3_3_123_2","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.3390\/cancers14122886","article-title":"A novel bispecific T-cell engager (CD1A x CD3\u03b5) BTCE is effective against cortical-derived T cell acute lymphoblastic leukemia (T-ALL) cells","volume":"14","author":"Riillo C","year":"2022","unstructured":"Riillo C, Caracciolo D, Grillone K, Poler\u00e0 N, Tuccillo FM, Bonelli P, Juli G, Ascrizzi S, Scionti F, Arbitrio M, et al. A novel bispecific T-cell engager (CD1A x CD3\u03b5) BTCE is effective against cortical-derived T cell acute lymphoblastic leukemia (T-ALL) cells. Cancer. 2022;14(12):2886.","journal-title":"Cancer"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-017-0102-y"},{"key":"e_1_3_3_126_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3390\/healthcare9081062","article-title":"Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR-T therapies for the treatment of cancer (1997\u20132020)","volume":"9","author":"Ivica NA","year":"2021","unstructured":"Ivica NA, Young CM. Tracking the CAR-T revolution: Analysis of clinical trials of CAR-T and TCR-T therapies for the treatment of cancer (1997\u20132020). Healthcare. 2021;9:1062.","journal-title":"Healthcare"},{"issue":"9","key":"e_1_3_3_127_2","doi-asserted-by":"crossref","first-page":"E2068","DOI":"10.1073\/pnas.1716266115","article-title":"Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity","volume":"115","author":"Davenport AJ","year":"2018","unstructured":"Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, et al. Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity. Proc Natl Acad Sci USA. 2018;115(9):E2068\u2013E2076.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4"},{"issue":"1","key":"e_1_3_3_129_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: The next revolution in cancer treatment","volume":"22","author":"Al-Haideri M","year":"2022","unstructured":"Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, Al-Gazally ME, Alsaikhan F, Rizaev JA, Mohammad TAM, et al. CAR-T cell combination therapy: The next revolution in cancer treatment. Cancer Cell Int. 2022;22(1):365.","journal-title":"Cancer Cell Int"},{"key":"e_1_3_3_130_2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang R","year":"2020","unstructured":"Huang R, Li X, He Y, Zhu W, Gao L, Liu Y, Gao L, Wen Q, Zhong JF, Zhang C, et al. Recent advances in CAR-T cell engineering. J Hematol Oncol. 2020;13:86.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"e_1_3_3_131_2","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.50","article-title":"Case report: Impact of BiTE on CAR-T cell expansion","volume":"2","author":"Shalabi H","year":"2019","unstructured":"Shalabi H, Koegel A, Ponduri A, Qin H, Salem D, Stetler-Stevenson M, Yuan C, Yates B, Delbrook C, Loh M, et al. Case report: Impact of BiTE on CAR-T cell expansion. Adv Cell Gene Ther. 2019;2(3): Article e50.","journal-title":"Adv Cell Gene Ther"},{"key":"e_1_3_3_132_2","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.1182\/blood-2023-190167","article-title":"Exploring BiTE-integrated CAR T-cell therapy to overcome tumor antigen escape and reinforce CAR-T therapy in mantle cell lymphoma","volume":"142","author":"Crutchfield GG","year":"2023","unstructured":"Crutchfield GG, Liu Y, Yan F, Li X, Lee H-H, Wang M, Yao Y. Exploring BiTE-integrated CAR T-cell therapy to overcome tumor antigen escape and reinforce CAR-T therapy in mantle cell lymphoma. Blood. 2023;142:6820.","journal-title":"Blood"},{"issue":"16","key":"e_1_3_3_133_2","first-page":"2550","article-title":"Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19\/CD22 CAR-T cells","volume":"42","author":"Arroyo-Rodenas J","year":"2024","unstructured":"Arroyo-Rodenas J, D\u00edez-Alonso L, Falgas A, Martinez-Moreno A, Gil-Etayo FJ, Aguilar-Sope\u00f1a \u00d3, Velasco-Sidro M, Bravo-Mart\u00edn C, Ram\u00edrez-Fern\u00e1ndez \u00c1, Jim\u00e9nez-Reinoso A, et al. Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19\/CD22 CAR-T cells. J Immunother Cancer. 2024;42(16_Supplement):2550\u20132550.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"issue":"10","key":"e_1_3_3_135_2","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of pegylation: Balancing PD with PK to generate novel therapeutics","volume":"97","author":"Simone C","year":"2008","unstructured":"Simone C, Fishburn. The pharmacology of pegylation: Balancing PD with PK to generate novel therapeutics. J Pharm Sci. 2008;97(10):4167\u20134183.","journal-title":"J Pharm Sci"},{"issue":"6","key":"e_1_3_3_136_2","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"Nanobodies: A review of generation, diagnostics and therapeutics","volume":"24","author":"Jin B-k","year":"2023","unstructured":"Jin B-k, Odongo S, Radwanska M, Magez S. Nanobodies: A review of generation, diagnostics and therapeutics. Int J Mol Sci. 2023;24(6):5994.","journal-title":"Int J Mol Sci"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01182"},{"issue":"1","key":"e_1_3_3_138_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1186\/s12951-024-02781-1","article-title":"A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects","volume":"22","author":"Xie S","year":"2024","unstructured":"Xie S, Shi W, Duan S, Huang X, Liu A, Hou X, Lin X, Zhong D, Sun S, Ding Z, et al. A nanobody-guided multifunctional T cell engager promotes strong anti-tumor responses via synergistic immuno-photothermal effects. J Nanobiotechnol. 2024;22(1):561.","journal-title":"J Nanobiotechnol"},{"key":"e_1_3_3_139_2","doi-asserted-by":"crossref","first-page":"1012841","DOI":"10.3389\/fimmu.2023.1012841","article-title":"Nanobodies in cell-mediated immunotherapy: On the road to fight cancer","volume":"14","author":"Maali A","year":"2023","unstructured":"Maali A, Gholizadeh M, Feghhi-Najafabadi S, Noei A, Seyed-Motahari SS, Mansoori S, Sharifzadeh Z. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer. Front Immunol. 2023;14:1012841.","journal-title":"Front Immunol"},{"issue":"7","key":"e_1_3_3_140_2","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1538-7445.AM2023-2928","article-title":"TROP2 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors","volume":"83","author":"Rocha SS","year":"2023","unstructured":"Rocha SS, Lin R, Dayao MR, Banzon RR, Thothathri S, Wright KJ, Aaron W, Xiao Y, Bergo N, To L, et al. TROP2 ProTriTAC\u2122, a protease-activated T cell engager prodrug targeting TROP2 for the treatment of solid tumors. Cancer Res. 2023;83(7_Supplement):2928\u20132928.","journal-title":"Cancer Res"},{"issue":"8","key":"e_1_3_3_141_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14712598.2022.2098674","article-title":"Conditionally active T cell engagers for the treatment of solid tumors: Rationale and clinical development","volume":"22","author":"Timothy T","year":"2022","unstructured":"Timothy T, Chen. Conditionally active T cell engagers for the treatment of solid tumors: Rationale and clinical development. Expert Opin Biol Ther. 2022;22(8):955\u2013963.","journal-title":"Expert Opin Biol Ther"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00536-9"},{"key":"e_1_3_3_143_2","doi-asserted-by":"crossref","first-page":"1792130","DOI":"10.1080\/19420862.2020.1792130","article-title":"Cobra\u2122: A highly potent conditionally active T cell engager engineered for the treatment of solid tumors","volume":"12","author":"Panchal A","year":"2020","unstructured":"Panchal A, Seto P, Wall R, Hillier BJ, Zhu Y, Krakow J, Datt A, Pongo E, Bagheri A, Chen T-HT, et al. Cobra\u2122: A highly potent conditionally active T cell engager engineered for the treatment of solid tumors. MAbs. 2020;12:1792130.","journal-title":"MAbs"},{"key":"e_1_3_3_144_2","doi-asserted-by":"crossref","first-page":"1490911","DOI":"10.3389\/fimmu.2024.1490911","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: Contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15","author":"Nolan-Stevaux O","year":"2024","unstructured":"Nolan-Stevaux O, Smith R. Logic-gated and contextual control of immunotherapy for solid tumors: Contrasting multi-specific T cell engagers and CAR-T cell therapies. Front Immunol. 2024;15:1490911.","journal-title":"Front Immunol"},{"key":"e_1_3_3_145_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2115213"},{"key":"e_1_3_3_146_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106781","article-title":"Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting","volume":"192","author":"Shen Y","year":"2023","unstructured":"Shen Y, Jin S-J, Chen Y-C, Liu W-H, Li Y-M, Zhao W-Y, Xu Y-C, Chen S-Q, Zhao W-B. Improving the tumor selectivity of T cell engagers by logic-gated dual tumor-targeting. Pharmacol Res. 2023;192: Article 106781.","journal-title":"Pharmacol Res"},{"key":"e_1_3_3_147_2","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2025.288473","article-title":"Characterization of JNJ-80948543, a novel CD79BxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma","author":"Kuchnio A","year":"2026","unstructured":"Kuchnio A, Yang D, Vloemans N, Lowenstein C, Cornelissen I, Amorim R, Han C, Sukumaran S, Janssen L, Suls T, et al. Characterization of JNJ-80948543, a novel CD79BxCD20xCD3 trispecific T-cell redirecting antibody for the treatment of B-cell non-Hodgkin lymphoma. Haematologica. 10.3324\/haematol.2025.28847. 2026.","journal-title":"Haematologica"},{"key":"e_1_3_3_148_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0692"},{"key":"e_1_3_3_149_2","doi-asserted-by":"crossref","first-page":"1411614","DOI":"10.3389\/fimmu.2024.1411614","article-title":"Mathematical models of TCR initial triggering","volume":"15","author":"Shi J","year":"2024","unstructured":"Shi J, Yin W, Chen W. Mathematical models of TCR initial triggering. Front Immunol. 2024;15:1411614.","journal-title":"Front Immunol"},{"issue":"11","key":"e_1_3_3_150_2","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1073\/pnas.92.11.5042","article-title":"Kinetic proofreading in T-cell receptor signal transduction","volume":"92","author":"McKeithan TW","year":"1995","unstructured":"McKeithan TW. Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci USA. 1995;92(11):5042\u20135046.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.3.1575"},{"key":"e_1_3_3_152_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12911-018-0606-x","article-title":"A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions","volume":"18","author":"Ganesan A","year":"2018","unstructured":"Ganesan A, Arulraj T, Choulli T, Barakat KH. A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. BMC Med Inform Decis Mak. 2018;18:37.","journal-title":"BMC Med Inform Decis Mak"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1480299"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-023-09846-y"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12369"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-020-00450-3"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0350-x"},{"key":"e_1_3_3_158_2","doi-asserted-by":"crossref","first-page":"1163432","DOI":"10.3389\/fphar.2023.1163432","article-title":"Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager","volume":"14","author":"Anbari S","year":"2023","unstructured":"Anbari S, Hanwen Wang Y, Zhang JW, Pilvankar M, Nickaeen M, Hansel S, Popel AS. Using quantitative systems pharmacology modeling to optimize combination therapy of anti-PD-L1 checkpoint inhibitor and T cell engager. Front Pharmacol. 2023;14:1163432.","journal-title":"Front Pharmacol"},{"issue":"1","key":"e_1_3_3_159_2","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1038\/s41598-022-14726-5","article-title":"Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma","volume":"12","author":"Abrams RE","year":"2022","unstructured":"Abrams RE, Pierre K, El-Murr N, Seung E, Wu L, Luna E, Mehta R, Li J, Larabi K, Ahmed M, et al. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma. Sci Rep. 2022;12(1):10976.","journal-title":"Sci Rep"},{"key":"e_1_3_3_160_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83659","article-title":"Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance","volume":"12","author":"Liu C","year":"2023","unstructured":"Liu C, Zhou J, Kudlacek S, Qi T, Dunlap T, Cao Y. Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. eLife. 2023;12: Article e83659.","journal-title":"eLife"},{"issue":"2","key":"e_1_3_3_161_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cpt.3302","article-title":"Optimizing clinical translation of bispecific T-cell engagers through context unification with a quantitative systems pharmacology model","volume":"116","author":"Liao X","year":"2024","unstructured":"Liao X, Qi T, Zhou J, Liu C, Cao Y. Optimizing clinical translation of bispecific T-cell engagers through context unification with a quantitative systems pharmacology model. Clin Pharmacol Ther. 2024;116(2):415\u2013425.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_3_162_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40262-024-01464-2","article-title":"Population pharmacokinetics of epcoritamab following subcutaneous administration in relapsed or refractory B cell non-Hodgkin lymphoma","volume":"64","author":"Li T","year":"2024","unstructured":"Li T, Gibiansky L, Parikh A, van der Linden M, Sanghavi K, Putnins M, Sacchi M, Feng H, Ahmadi T, Gupta M, et al. Population pharmacokinetics of epcoritamab following subcutaneous administration in relapsed or refractory B cell non-Hodgkin lymphoma. Clin Pharmacokinet. 2024;64:127\u2013141.","journal-title":"Clin Pharmacokinet"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0405-4"},{"key":"e_1_3_3_164_2","doi-asserted-by":"crossref","first-page":"viii139","DOI":"10.1093\/annonc\/mdy279.413","article-title":"Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas","volume":"29","author":"Moek KL","year":"2018","unstructured":"Moek KL, Waaijer SJH, Kok IC, Suurs FV, Brouwers A, Wind TT, Gietema JA, Schroder CP, Mahesh SVK, Jorritsma-Smit A, et al. Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas. Ann Oncol. 2018;29:viii139.","journal-title":"Ann Oncol"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.4161\/19420862.2014.975660"},{"issue":"10","key":"e_1_3_3_166_2","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-21-0355","article-title":"BiTE-ing into prostate cancer with bispecific T-cell engagers","volume":"27","author":"Kamat NV","year":"2021","unstructured":"Kamat NV, Yu EY, Lee JK. BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin Cancer Res. 2021;27(10):2675\u20132677.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0256"},{"issue":"8","key":"e_1_3_3_168_2","article-title":"A multicenter phase 1 study of solitomab (MT110, Amg 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE) antibody construct, in patients with refractory solid tumors","volume":"7","author":"Kebenko M","year":"2018","unstructured":"Kebenko M, Goebeler M-E, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, et al. A multicenter phase 1 study of solitomab (MT110, Amg 110), a bispecific EpCAM\/CD3 T-cell engager (BiTE) antibody construct, in patients with refractory solid tumors. Onco Targets Ther. 2018;7(8): Article e1450710.","journal-title":"Onco Targets Ther"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2265"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007732"},{"key":"e_1_3_3_171_2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood-2019-129042","article-title":"Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2: 2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"134","author":"Westervelt P","year":"2019","unstructured":"Westervelt P, Cortes JE, Altman JK, Long M, Oehler VG, Gojo I, Guenot J, Chun P, Roboz GJ. Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2: 2) CD33\/CD3 T-cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Blood. 2019;134:834.","journal-title":"Blood"},{"issue":"6","key":"e_1_3_3_172_2","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2022.02.005","article-title":"Immunodepletion of mdsc by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex\u00a0vivo in MDS and melanoma","volume":"30","author":"Cheng P","year":"2022","unstructured":"Cheng P, Chen X, Dalton R, Calescibetta A, So T, Gilvary D, Ward G, Smith V, Eckard S, Fox JA, et al. Immunodepletion of mdsc by AMV564, a novel bivalent, bispecific CD33\/CD3 T cell engager, ex\u00a0vivo in MDS and melanoma. Mol Ther. 2022;30(6):2315\u20132326.","journal-title":"Mol Ther"},{"issue":"13","key":"e_1_3_3_173_2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1158\/1538-7445.AM2017-55","article-title":"Generation of half-life extended anti-CD33 BiTE antibody constructs compatible with once-weekly dosing","volume":"77","author":"Arvedson TL","year":"2017","unstructured":"Arvedson TL, Balazs M, Bogner P, Black K, Graham K, Henn A, Friedrich M, Hoffmann P, Kischel R, Kufer P, et al. Generation of half-life extended anti-CD33 BiTE antibody constructs compatible with once-weekly dosing. Cancer Res. 2017;77(13_Supplement):55.","journal-title":"Cancer Res"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0956"},{"issue":"17","key":"e_1_3_3_175_2","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma","volume":"40","author":"Carvajal RD","year":"2022","unstructured":"Carvajal RD, Nathan P, Sacco JJ, Orloff M, Hernandez-Aya LF, Yang J, Luke JJ, Butler MO, Stanhope S, Collins L, et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J Clin Oncol. 2022;40(17):1939\u20131948.","journal-title":"J Clin Oncol"},{"issue":"12","key":"e_1_3_3_176_2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181464","article-title":"Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients","volume":"135","author":"Staeger R","year":"2025","unstructured":"Staeger R, Tastanova A, Ghosh A, Winkelbeiner N, Shukla P, Kolm I, Turko P, Benlahrech A, Harper J, Broomfield A, et al. Tebentafusp elicits on-target cutaneous immune responses driven by cytotoxic T cells in uveal melanoma patients. J Clin Invest. 2025;135(12): Article e181464.","journal-title":"J Clin Invest"},{"key":"e_1_3_3_177_2","unstructured":"U.S. Food and Drug Administration tarlatamab label. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761344s000lbl.pdf"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.3390\/antib5010006"},{"key":"e_1_3_3_179_2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845417","article-title":"A phase 1 dose-escalation study of PF-06671008, a bispecific T-cell-engaging therapy targeting P-cadherin in patients with advanced solid tumors","volume":"13","author":"Harding JJ","year":"2022","unstructured":"Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, et al. A phase 1 dose-escalation study of PF-06671008, a bispecific T-cell-engaging therapy targeting P-cadherin in patients with advanced solid tumors. Front Immunol. 2022;13: Article 845417.","journal-title":"Front Immunol"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0666"},{"key":"e_1_3_3_181_2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood-2023-182345","article-title":"Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM)","volume":"142","author":"Madan S","year":"2023","unstructured":"Madan S, Costello CL, Lipe B, Cowan AJ, Medvedova E, Jens Hillengass P, Bergsagel L, Leleu X, Touzeau C, Morillo D, et al. Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM). Blood. 2023;142:1012.","journal-title":"Blood"},{"key":"e_1_3_3_182_2","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1182\/blood-2023-182086","article-title":"Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma (r\/r NHL)","volume":"142","author":"Bender BC","year":"2023","unstructured":"Bender BC, Li C-C, Marchand M, Turner DC, Li F, Vadhavkar S, Wang B, Deng R, James L, Jin J, et al. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell non-Hodgkin lymphoma (r\/r NHL). Blood. 2023;142:2810.","journal-title":"Blood"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2404079"},{"issue":"1","key":"e_1_3_3_184_2","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13717","article-title":"Teclistamab: Mechanism of action, clinical, and translational science","volume":"17","author":"Guo Y","year":"2024","unstructured":"Guo Y, Quijano NA, Card\u00e9 LK, Verona R, Banerjee A, Kobos R, Chastain K, Uhlar C, Pillarisetti K, Doyle M, et al. Teclistamab: Mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1): Article e13717.","journal-title":"Clin Transl Sci"},{"issue":"12","key":"e_1_3_3_185_2","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont C","year":"2023","unstructured":"Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: Dose expansion in a phase I\/II trial. J Clin Oncol. 2023;41(12):2238\u20132247.","journal-title":"J Clin Oncol"},{"issue":"8","key":"e_1_3_3_186_2","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (epcore nhl-1): A phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton KM","year":"2024","unstructured":"Linton KM, Vitolo U, Jurczak W, Lugtenburg PJ, Gyan E, Sureda A, Christensen JH, Hess B, Tilly H, Cordoba R, et al. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (epcore nhl-1): A phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024;11(8):e593\u2013e605.","journal-title":"Lancet Haematol"},{"key":"e_1_3_3_187_2","unstructured":"U.S. Food and Drug Administration glofitamab label. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761309s000lbl.pdf"},{"key":"e_1_3_3_188_2","unstructured":"U.S. Food and Drug Administration elranatamab label. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345Orig1s000lbl.pdf"},{"issue":"1","key":"e_1_3_3_189_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ejh.70167","article-title":"Elranatamab in relapsed\/refractory multiple myeloma: Mechanisms, clinical evidence, and emerging perspectives","volume":"117","author":"Alvaro ME","year":"2026","unstructured":"Alvaro ME, Martino EA, Caserta S, Skafi M, Bruzzese A, Amodio N, Lucia E, Olivito V, Labanca C, Mendicino F, et al. Elranatamab in relapsed\/refractory multiple myeloma: Mechanisms, clinical evidence, and emerging perspectives. Eur J Haematol. 2026;117(1):42\u201354.","journal-title":"Eur J Haematol"},{"key":"e_1_3_3_190_2","unstructured":"U.S. Food and Drug Administration talquetamab label. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14353"},{"issue":"3","key":"e_1_3_3_192_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cpt.3353","article-title":"Informing the recommended phase III dose of alnuctamab, a CD3\u00d7 BCMA T-cell engager, using population pharmacokinetics and exposure\u2013response analysis","volume":"116","author":"Kiesel B","year":"2024","unstructured":"Kiesel B, Osawa M, Masilamani M, Bar M, Hsu K, Godwin C, Burgess M, Lamba M, Gaudy A. Informing the recommended phase III dose of alnuctamab, a CD3\u00d7 BCMA T-cell engager, using population pharmacokinetics and exposure\u2013response analysis. Clin Pharmacol Ther. 2024;116(3):866\u2013874.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_3_193_2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41375-025-02841-x","article-title":"Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: Results from a phase 1, first-in-human study","volume":"40","author":"Bar N","year":"2026","unstructured":"Bar N, Martin T, Hofmeister CC, Mateos M-V, Hansson M, Paris L, Namburi S, Ribas P, Santoro A, Rodriguez-Otero P, et al. Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: Results from a phase 1, first-in-human study. Leukemia. 2026;40:481\u2013490.","journal-title":"Leukemia"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.34133\/csbj.0209","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:01:30Z","timestamp":1789113690000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.34133\/csbj.0209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":192,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.34133\/csbj.0209"],"URL":"https:\/\/doi.org\/10.34133\/csbj.0209","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"0209"}}